PMID- 34673386 OWN - NLM STAT- MEDLINE DCOM- 20220325 LR - 20240123 IS - 1573-2509 (Electronic) IS - 0920-9964 (Print) IS - 0920-9964 (Linking) VI - 238 DP - 2021 Dec TI - Association between residential instability at individual and area levels and future psychosis in adolescents at clinical high risk from the North American Prodrome Longitudinal Study (NAPLS) consortium. PG - 137-144 LID - S0920-9964(21)00395-9 [pii] LID - 10.1016/j.schres.2021.09.025 [doi] AB - OBJECTIVE: Accumulating evidence supports an association between residential instability and increased risk for psychosis, but the association between residential instability and conversion to psychosis among adolescents at clinical high risk (CHR) is unclear. In this study, we determined whether individual-level and area-level residential instability and their interaction are associated with conversion to psychosis within two years. METHODS: Data were collected as part of the North American Prodrome Longitudinal Study Phase 2. Individual-level residential instability, defined as having ever moved during lifetime, was derived from the Life Events Scale. Area-level residential instability, defined as the percentage of people who were not living in the same house five years ago, was derived from the U.S. Decennial Censuses. RESULTS: This study included 285 adolescents at CHR (including 36 subjects who later converted to full psychosis). We found that individual-level residential instability was associated with conversion (adjusted OR = 2.769; 95% CI = 1.037-7.393). The interaction between individual-level and area-level residential instability was significant (p = 0.030). In a subgroup of CHR participants who have never moved (n = 91), area-level residential instability during childhood was associated with conversion (adjusted OR = 1.231; 95% CI = 1.029-1.473). Conversely, in a subgroup of CHR participants who resided in residentially stable areas during childhood (n = 142), the association between individual-level residential instability and conversion remained significant (adjusted OR = 15.171; 95% CI = 1.753-131.305). CONCLUSIONS: These findings suggest that individual-level and area-level residential instability may be associated with conversion to psychosis. CI - Copyright (c) 2021 Elsevier B.V. All rights reserved. FAU - Ku, Benson S AU - Ku BS AD - Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, United States. Electronic address: bsku@emory.edu. FAU - Addington, Jean AU - Addington J AD - Department of Psychiatry, University of Calgary, Calgary, Alberta, Canada. FAU - Bearden, Carrie E AU - Bearden CE AD - Department of Psychiatry and Biobehavioral Sciences and Psychology, UCLA, Los Angeles, United States. FAU - Cadenhead, Kristin S AU - Cadenhead KS AD - Department of Psychiatry, University of California, San Diego, CA, United States. FAU - Cannon, Tyrone D AU - Cannon TD AD - Department of Psychiatry, Yale University, New Haven, CT, United States. FAU - Compton, Michael T AU - Compton MT AD - Department of Psychiatry, Columbia University Vagelos College of Physicians and Surgeons, New York State Psychiatric Institute, New York, NY, United States. FAU - Cornblatt, Barbara A AU - Cornblatt BA AD - Department of Psychiatry, Zucker Hillside Hospital, Long Island, NY, United States. FAU - Keshavan, Matcheri AU - Keshavan M AD - Harvard Medical School, Departments of Psychiatry at Massachusetts Mental Health Center Public Psychiatry Division, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Boston, MA, United States. FAU - Mathalon, Daniel H AU - Mathalon DH AD - Department of Psychiatry, University of California, San Francisco Veterans Affairs Medical Center, San Francisco, CA, United States. FAU - Perkins, Diana O AU - Perkins DO AD - Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States. FAU - Stone, William S AU - Stone WS AD - Harvard Medical School, Departments of Psychiatry at Massachusetts Mental Health Center Public Psychiatry Division, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Boston, MA, United States. FAU - Tsuang, Ming T AU - Tsuang MT AD - Department of Psychiatry, University of California, San Diego, CA, United States. FAU - Walker, Elaine F AU - Walker EF AD - Department of Psychology, Emory University, Atlanta, GA, United States. FAU - Woods, Scott W AU - Woods SW AD - Department of Psychiatry, Yale University, New Haven, CT, United States. FAU - Druss, Benjamin G AU - Druss BG AD - Department of Health Policy and Management, Rollins School of Public Health, Emory University, Atlanta, GA, United States. LA - eng GR - U01 MH082022/MH/NIMH NIH HHS/United States GR - R25 MH101079/MH/NIMH NIH HHS/United States GR - U01 MH081902/MH/NIMH NIH HHS/United States GR - R01 MH076989/MH/NIMH NIH HHS/United States GR - U01 MH081988/MH/NIMH NIH HHS/United States GR - U01 MH066069/MH/NIMH NIH HHS/United States GR - P50 MH066286/MH/NIMH NIH HHS/United States GR - U01 MH066134/MH/NIMH NIH HHS/United States GR - U01 MH081857/MH/NIMH NIH HHS/United States GR - U01 MH081944/MH/NIMH NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20211019 PL - Netherlands TA - Schizophr Res JT - Schizophrenia research JID - 8804207 SB - IM MH - Adolescent MH - Humans MH - Longitudinal Studies MH - North America/epidemiology MH - *Prodromal Symptoms MH - *Psychotic Disorders/epidemiology PMC - PMC10800030 MID - NIHMS1951420 OTO - NOTNLM OT - Clinical high risk for psychosis OT - Prodrome OT - Residential instability COIS- Declaration of competing interest Dr. Cannon has served as a consultant for Boehringer-Ingelheim Pharmaceuticals and Lundbeck A/S. Dr. Mathalon has served as a consultant for Aptinyx, Boehringer-Ingelheim Pharmaceuticals, Cadent Therapeutics, and Greenwich Biosciences. Dr. Perkins has served as a consultant for Sunovion and Alkermes, has received research support from Boehringer-Ingelheim, and has received royalties from American Psychiatric Association Publishing. Dr. Woods has received investigator-initiated research support from Pfizer and sponsor-initiated research support from Auspex and Teva; he has served as a consultant for Biomedisyn (unpaid), Boehringer-Ingelheim, and Merck and as an unpaid consultant to DSM-5; he has been granted a patent for a method of treating prodromal schizophrenia with glycine; and he has received royalties from Oxford University Press. The other authors report no financial relationships with commercial interests. EDAT- 2021/10/22 06:00 MHDA- 2022/03/26 06:00 PMCR- 2024/01/21 CRDT- 2021/10/21 21:00 PHST- 2020/06/08 00:00 [received] PHST- 2021/09/09 00:00 [revised] PHST- 2021/09/27 00:00 [accepted] PHST- 2021/10/22 06:00 [pubmed] PHST- 2022/03/26 06:00 [medline] PHST- 2021/10/21 21:00 [entrez] PHST- 2024/01/21 00:00 [pmc-release] AID - S0920-9964(21)00395-9 [pii] AID - 10.1016/j.schres.2021.09.025 [doi] PST - ppublish SO - Schizophr Res. 2021 Dec;238:137-144. doi: 10.1016/j.schres.2021.09.025. Epub 2021 Oct 19.